Model for calculating the risk of venous thrombosis

Aim. To develop a model for calculating the risk of venous thrombosis, taking into account the presence of known risk factors, comorbidity and congenital thrombophilia.Material and methods. During the study (2015 to 2017), 79 patients with venous thrombosis were examined (36 men and 43 women, mean a...

Full description

Bibliographic Details
Main Authors: A. V. Golub, I. N. Bokarev, L. V. Popova, A. N. Gerasimov, M. Z. Kanevskaya, T. V. Khlevchuk, T. V. Kondratieva, M. B. Aksenova, L. V. Patrushev, T. F. Kovalenko, Yu. N. Belenkov
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2019-06-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/3102
_version_ 1797856758298836992
author A. V. Golub
I. N. Bokarev
L. V. Popova
A. N. Gerasimov
M. Z. Kanevskaya
T. V. Khlevchuk
T. V. Kondratieva
M. B. Aksenova
L. V. Patrushev
T. F. Kovalenko
Yu. N. Belenkov
author_facet A. V. Golub
I. N. Bokarev
L. V. Popova
A. N. Gerasimov
M. Z. Kanevskaya
T. V. Khlevchuk
T. V. Kondratieva
M. B. Aksenova
L. V. Patrushev
T. F. Kovalenko
Yu. N. Belenkov
author_sort A. V. Golub
collection DOAJ
description Aim. To develop a model for calculating the risk of venous thrombosis, taking into account the presence of known risk factors, comorbidity and congenital thrombophilia.Material and methods. During the study (2015 to 2017), 79 patients with venous thrombosis were examined (36 men and 43 women, mean age — 56,76±15,570). The control group consisted of 83 patients and healthy volunteers without thrombosis at the moment and in history (35 men and 48 women, average age — 43,95±18,136). All individuals included in the study were analyzed for the presence of G1691A mutations in the factor V gene, G20210A in the prothrombin gene, C677T polymorphism in the 5,10-methylenetetrahydrofolate reductase gene, and polymorphism in the SERPINE1 gene of plasminogen activator inhibitor. Real-time polymerase chain reaction was used to identify mutations. To create a risk calculation model, a linear regression analysis was performed.Results. We have developed a model for calculating the risk of venous thrombosis. The resulting formula showed high prognostic accuracy (the area under the ROC curve is 95,9%). For patients who do not have data on the presence of these mutations, a short version of the risk calculation model was developed (the area under the ROC curve is 94,6%).Conclusion. We have developed a risk calculation model taking into account the presence of known risk factors, congenital thrombophilia and comorbidities. Thromboprophylaxis is necessary in >0,45 individual risk, which corresponds to a high risk of developing venous thrombosis. Patients who have not previously been diagnosed with thrombophilia and are in the middle risk group for venous thrombosis, according to a short version of the model, must be screened for congenital thrombophilia to clarify the risk.
first_indexed 2024-04-09T20:46:40Z
format Article
id doaj.art-8961acc474db47aaa114c103bacc3d00
institution Directory Open Access Journal
issn 1560-4071
2618-7620
language Russian
last_indexed 2024-04-09T20:46:40Z
publishDate 2019-06-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj.art-8961acc474db47aaa114c103bacc3d002023-03-29T21:23:33Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202019-06-0105374310.15829/1560-4071-2019-5-37-432582Model for calculating the risk of venous thrombosisA. V. Golub0I. N. Bokarev1L. V. Popova2A. N. Gerasimov3M. Z. Kanevskaya4T. V. Khlevchuk5T. V. Kondratieva6M. B. Aksenova7L. V. Patrushev8T. F. Kovalenko9Yu. N. Belenkov10A.K. Eramishantsev City Clinical HospitalA.A. Schmidt-B. A. Kudryashov All-Russian Association for the Study of thrombosis, hemorrhage and vascular pathologyI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityM.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic ChemistryI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityM. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic ChemistryM.M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic ChemistryI.M. Sechenov First Moscow State Medical UniversityAim. To develop a model for calculating the risk of venous thrombosis, taking into account the presence of known risk factors, comorbidity and congenital thrombophilia.Material and methods. During the study (2015 to 2017), 79 patients with venous thrombosis were examined (36 men and 43 women, mean age — 56,76±15,570). The control group consisted of 83 patients and healthy volunteers without thrombosis at the moment and in history (35 men and 48 women, average age — 43,95±18,136). All individuals included in the study were analyzed for the presence of G1691A mutations in the factor V gene, G20210A in the prothrombin gene, C677T polymorphism in the 5,10-methylenetetrahydrofolate reductase gene, and polymorphism in the SERPINE1 gene of plasminogen activator inhibitor. Real-time polymerase chain reaction was used to identify mutations. To create a risk calculation model, a linear regression analysis was performed.Results. We have developed a model for calculating the risk of venous thrombosis. The resulting formula showed high prognostic accuracy (the area under the ROC curve is 95,9%). For patients who do not have data on the presence of these mutations, a short version of the risk calculation model was developed (the area under the ROC curve is 94,6%).Conclusion. We have developed a risk calculation model taking into account the presence of known risk factors, congenital thrombophilia and comorbidities. Thromboprophylaxis is necessary in >0,45 individual risk, which corresponds to a high risk of developing venous thrombosis. Patients who have not previously been diagnosed with thrombophilia and are in the middle risk group for venous thrombosis, according to a short version of the model, must be screened for congenital thrombophilia to clarify the risk.https://russjcardiol.elpub.ru/jour/article/view/3102congenital thrombophiliaoverweightobesityvenous thrombosis of the lower extremitiespulmonary embolismrisk calculation model
spellingShingle A. V. Golub
I. N. Bokarev
L. V. Popova
A. N. Gerasimov
M. Z. Kanevskaya
T. V. Khlevchuk
T. V. Kondratieva
M. B. Aksenova
L. V. Patrushev
T. F. Kovalenko
Yu. N. Belenkov
Model for calculating the risk of venous thrombosis
Российский кардиологический журнал
congenital thrombophilia
overweight
obesity
venous thrombosis of the lower extremities
pulmonary embolism
risk calculation model
title Model for calculating the risk of venous thrombosis
title_full Model for calculating the risk of venous thrombosis
title_fullStr Model for calculating the risk of venous thrombosis
title_full_unstemmed Model for calculating the risk of venous thrombosis
title_short Model for calculating the risk of venous thrombosis
title_sort model for calculating the risk of venous thrombosis
topic congenital thrombophilia
overweight
obesity
venous thrombosis of the lower extremities
pulmonary embolism
risk calculation model
url https://russjcardiol.elpub.ru/jour/article/view/3102
work_keys_str_mv AT avgolub modelforcalculatingtheriskofvenousthrombosis
AT inbokarev modelforcalculatingtheriskofvenousthrombosis
AT lvpopova modelforcalculatingtheriskofvenousthrombosis
AT angerasimov modelforcalculatingtheriskofvenousthrombosis
AT mzkanevskaya modelforcalculatingtheriskofvenousthrombosis
AT tvkhlevchuk modelforcalculatingtheriskofvenousthrombosis
AT tvkondratieva modelforcalculatingtheriskofvenousthrombosis
AT mbaksenova modelforcalculatingtheriskofvenousthrombosis
AT lvpatrushev modelforcalculatingtheriskofvenousthrombosis
AT tfkovalenko modelforcalculatingtheriskofvenousthrombosis
AT yunbelenkov modelforcalculatingtheriskofvenousthrombosis